NBIX News and Press, Neurocrine Biosciences Inc. From 03/28/22

Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022 PR Newswire SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc...

Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting PR Newswire SAN DIEGO , March 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) ...

Neurocrine Biosciences to Present at Stifel 2022 CNS Days PR Newswire SAN DIEGO , March 21, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2022 CNS Days virtual conference at 3:30 p.m. Eastern Time on Monday ...

Piper Sandler has downgraded Neurocrine Biosciences (NBIX -4.6%) to neutral from overweight amid concerns of more modest long-term growth of its tardive dyskinesia ("TD") treatment Ingrezza (valbenazine). The firm also lowered its price target to $94 from $114 (~2% upside based on Wednesday's...

Inflation is back. It’s back in a major way. The consumer price index for all items rose 0.6% in January, driving up annual inflation by 7.5%. That marked the biggest gain since February 1982 and was even higher than the Wall Street estimate. (3) It’s taking its toll on everyone...

Goldman Sachs has upgraded shares of Neurocrine Biosciences (NBIX +1.2%) to buy from hold based on its solid balance sheet and catalysts coming in the next 12-18 months. The firm is maintaining its $115 price target (~32% upside based on Thursday's close.) Analyst Chris Shibutani said that he...

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...

Neurocrine exited 2021 with high single-digit qoq growth in Ingrezza prescriptions, but management is investing even more SG&A resources into recharging sales growth and momentum. Neurocrine has a large pipeline in terms of compounds and addressable indications, but the vast major...

The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...

Image source: The Motley Fool. Neurocrine Biosciences (NASDAQ: NBIX) Q4 2021 Earnings Call Feb 11, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript